Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response - Tsai, Shih-Jen; Hong, Chen-Jee; Liou, Ying-Jay; Yu, Younger W-Y; Chen, Tai-Jui; Hou, Sheue-Jane; Yen, Feng-Chang (Progress in neuro-psychopharmacology & biological psychiatry, 2009)
Keywords: Adult; Adult and adolescent clinical studies; Antidepressant; Antidepressive Agents - therapeutic use; Biological and medical sciences; Citalopram; Depression; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - genetics; Female; Fluoxetine; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Major depressive disorders; Male; Medical sciences; Middle Aged; Mood disorders; Neuropharmacology; Pharmacogenetics; Pharmacology. Drug treatments; Polymorphism; Polymorphism, Single Nucleotide - genetics; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Serotonin Uptake Inhibitors - therapeutic use; Taiwan; Tryptophan Hydroxylase - genetics; Tryptophan hydroxylase 2; Asia; China; Taiwan; Antidepressant; Pharmacogenetics; MDD; TPH; SSRI; SNP; Tryptophan hydroxylase 2; LD; HPA; SCAN; CHB; HAM-D; Major depressive disorders; Polymorphism; Mood disorder; Genetic variability; Serotonin; Healthy subject; Fluoxetine; Psychotropic; Etiopathogenesis; Depression; Reuptake inhibitor; Selective serotonin reuptake inhibitor; Citalopram; Treatment; Gene; Genetics; Antidepressant agent; Comparative study